Prior Anti-CTLA-4 Therapy Impacts Molecular Characteristics Associated with Anti-PD-1 Response in Advanced Melanoma

Investigators analyzed seven molecular datasets of samples from patients with advanced melanoma treated with immune checkpoint inhibitor agents to investigate clinical, genomic, and transcriptomic features of anti-PD-1 response in cutaneous melanoma.